The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now ...

(RTTNews) - Sanofi said that the U.S. Food and Drug Administration has approved a Biologics License Application for MenQuadfi Meningococcal Conjugate Vaccine for the prevention of invasive ...

Sanofi's MenQuadfi (quadrivalent polysaccharide tetanus toxoid conjugate vaccine) is a second-generation active polyvalent conjugate vaccine against group A, C, Y, and W meningococcal infection.

If approved, MenQuadfi will be available in a fully liquid presentation. Phase II and Phase III trials have been performed in the U.S., the European Union (EU), Asia and Latin America. Sanofi is ...

Sanofi SNY announced that the European Commission (EC) has approved its fully-liquid meningococcal vaccine MenQuadfi for the active immunization of individuals, aged 12 months and above against ...

Sanofi (SNY)'s share was trading at $51.06 ... by deep public-sector distribution—generated €2.25 billion, and MenQuadfi, a meningitis vaccine, posted 50.5% growth. Despite some expected ...

Sanofi provided a breakdown on how it arrived at the price for each of its three drugs that were launched in 2021—Pompe disease treatment Nexviazyme and two vaccines, Vaxelis and MenQuadfi.

Perspective from Kwang Sik Kim, MD MenQuadfi (Sanofi Pasteur) is the first FDA-approved quadrivalent meningococcal vaccine that uses tetanus toxoid as a protein carrier, the release said.